Consumer medicine information

Ropivacaine ReadyfusOR

Ropivacaine hydrochloride

BRAND INFORMATION

Brand name

Ropivacaine ReadyfusOR

Active ingredient

Ropivacaine hydrochloride

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Ropivacaine ReadyfusOR.

SUMMARY CMI

Ropivacaine ReadyfusOR

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I using Ropivacaine ReadyfusOR?

Ropivacaine ReadyfusOR contains the active ingredient ropivacaine hydrochloride. Ropivacaine ReadyfusOR is used in adults after surgery to treat post-operative pain.

For more information, see Section 1. Why am I using Ropivacaine ReadyfusOR? in the full CMI.

2. What should I know before I use Ropivacaine ReadyfusOR?

Do not use if you have ever had an allergic reaction to Ropivacaine ReadyfusOR or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I use Ropivacaine ReadyfusOR? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with Ropivacaine ReadyfusOR and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use Ropivacaine ReadyfusOR?

Your doctor will have had a lot of experience using ropivacaine hydrochloride or other local anaesthetics, and will choose the best dose for you.

Your doctor will inject the medicine in the Ropivacaine ReadyfusOR into the skin, near a single nerve, or into an area which contains a large number of nerves. It may also be directed into a surgical incision after surgery by a tube.

More instructions can be found in Section 4. How do I use Ropivacaine ReadyfusOR? in the full CMI.

5. What should I know while using Ropivacaine ReadyfusOR?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using Ropivacaine ReadyfusOR.
Driving or using machines
  • Be careful before you drive or use any machines or tools until you know how Ropivacaine ReadyfusOR affects you.
Drinking alcohol
  • Do not drink alcohol while you are fitted with the Ropivacaine ReadyfusOR.

For more information, see Section 5. What should I know while using Ropivacaine ReadyfusOR? in the full CMI.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary.

The most common side effects are nausea (feeling sick), dizziness, irregular or slow heartbeat, a tingling feeling ("pins and needles"), difficulty sleeping (insomnia), fever, back pain, headache, vomiting, difficulty passing urine, pain in the chest, shivering.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

Ropivacaine ReadyfusOR

Active ingredient: ropivacaine hydrochloride

Consumer Medicine Information (CMI)

This leaflet provides important information about using Ropivacaine ReadyfusOR. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Ropivacaine ReadyfusOR.

Where to find information in this leaflet:

1. Why am I using Ropivacaine ReadyfusOR?
2. What should I know before I use Ropivacaine ReadyfusOR?
3. What if I am taking other medicines?
4. How do I use Ropivacaine ReadyfusOR?
5. What should I know while using Ropivacaine ReadyfusOR?
6. Are there any side effects?
7. Product details

1. Why am I using Ropivacaine ReadyfusOR?

Ropivacaine ReadyfusOR contains a local anaesthetic called ropivacaine hydrochloride, which is already inside the dispenser. The local anaesthetic is injected into the body where it makes the nerves unable to pass messages to the brain.

Depending on the amount used, it will either totally stop pain or will cause a partial loss of feeling.

Ropivacaine ReadyfusOR is used in adults after surgery to treat post-operative pain.

Your doctor will have explained why you are being treated with ropivacaine hydrochloride and will have told you about the length of time you will be treated and the dose you will be given.

Follow all directions given to you by your doctor carefully.

They may differ from the information contained in this leaflet.

Your doctor may prescribe this medicine for another use. Ask your doctor if you want more information.

Ropivacaine hydrochloride, the medicine in Ropivacaine ReadyfusOR, is not addictive.

2. What should I know before I use Ropivacaine ReadyfusOR?

Warnings

Do not use Ropivacaine ReadyfusOR if:

  • you are allergic to:
    - ropivacaine hydrochloride
    - any of the ingredients listed at the end of this leaflet
    - any other local anaesthetics
    Always check the ingredients to make sure you can use this medicine.
  • you have problems controlling your low blood pressure
  • you have inflammation and/or an infection at the site of the injection

Check with your doctor if you:

  • have any allergies to other substances
  • have any of these medical conditions:
    - problems with your blood pressure or circulation
    - blood poisoning
    - problems with the clotting of your blood
    - acidosis, or too much acid in the blood
    - nerve problems
    - liver, kidney or heart problems
    - disease of the brain or spine, including meningitis, polio, cancer or infection
    - muscle disease or weakness (e.g. myasthenia gravis)
    It may not be safe for you to use Ropivacaine ReadyfusOR if you have any of these conditions.
  • have any other medical condition
  • take any medicines for any other condition

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

Your doctor will discuss the possible risks and benefits of using Ropivacaine ReadyfusOR during pregnancy and breastfeeding.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with Ropivacaine ReadyfusOR and affect how it works. These include:

  • medicines that control your heartbeat
  • medicines used to thin the blood, including aspirin
  • low molecular weight heparin or other medicines used to prevent blood clots
  • fluvoxamine, a medicine used to treat depression
  • enoxacin, a medicine used to treat bacterial infections
  • ketoconazole, a medicine used to treat fungal infections
  • cimetidine, a medicine used to treat stomach ulcers or heartburn
  • medicines for depression

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect Ropivacaine ReadyfusOR.

4. How do I use Ropivacaine ReadyfusOR?

How much to use

  • Your doctor will have had a lot of experience using ropivacaine hydrochloride or other local anaesthetics, and will choose the best dose for you. They will be willing to discuss this decision with you.

How it will be used

  • Ropivacaine ReadyfusOR should only be used by or under the supervision of doctors experienced in regional anaesthesia.
  • Refer to the Package Insert for detailed instructions for use of the Ropivacaine ReadyfusOR product.
  • The Ropivacaine ReadyfusOR is intended for single use only, and the dispenser should be discarded after single use.
  • The medicine in the Ropivacaine ReadyfusOR will be injected by your doctor into the skin, near a single nerve, or into the skin, near a single nerve, or into an area which contains a large number of nerves. It may also be directed into the surgical incision after surgery by a tube.
  • This will result in an area of numbness at or near the site of administration.
  • The medicine in Ropivacaine ReadyfusOR is ropivacaine hydrochloride and it should not be injected directly into the blood.

If you use too much Ropivacaine ReadyfusOR

The doctor giving you ropivacaine hydrochloride will be experienced in the use of local anaesthetics, so it is unlikely that you will be given too much.

However, if you are particularly sensitive to ropivacaine hydrochloride, or the dose is accidentally injected directly into your blood, you may develop problems with your sight, hearing, and get a numb feeling in or around the mouth, feel dizzy or stiff, or have twitchy muscles.

In rare cases, these effects may be followed by drowsiness and fits. In extreme cases you may have problems with your breathing or your heart and you may become unconscious.

If you think that you have been given too much Ropivacaine ReadyfusOR, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while using Ropivacaine ReadyfusOR?

Things you should do

Remind any doctor, dentist, nurse or pharmacist you visit that you are using Ropivacaine ReadyfusOR.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how Ropivacaine ReadyfusOR affects you.

Ropivacaine ReadyfusOR may cause dizziness in some people.

Drinking alcohol

Do not drink alcohol while you are fitted with the Ropivacaine ReadyfusOR.

If you drink alcohol while you are being given ropivacaine hydrochloride your blood pressure may drop making you feel dizzy and faint.

Getting rid of any unwanted medicine

Ropivacaine ReadyfusOR is for single use only.

The Ropivacaine ReadyfusOR will be disposed of in a safe manner by your doctor or nurse after you have used it, even if there is some ropivacaine hydrochloride solution left in the dispenser.

Ropivacaine ReadyfusOR will only be used if the solution is clear, the package is undamaged and the use by (expiry) date marked on the pack has not been passed.

6. Are there any side effects?

Ropivacaine ReadyfusOR will help relieve pain in most people, but it may have some unwanted side effects.

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Tell your doctor or a nurse as soon as possible if you do not feel well while you are fitted with Ropivacaine ReadyfusOR.

Less serious side effects

Less serious side effectsWhat to do
Gut related
  • Nausea (feeling sick)
  • Vomiting
Brain and nervous system related
  • Headache
  • Dizziness
  • A tingling feeling ("pins and needles")
  • Shivering
  • Difficulty sleeping
  • Nervousness
  • Decreased feeling or sensitivity, especially in the skin
Heart related
  • Irregular or slow heartbeat
Urine related
  • Difficulty passing urine
Other
  • Fever
  • Back pain
Tell your doctor or a nurse if you notice any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
Heart related
  • Slow heartbeat
Brain and nervous system related
  • Extreme dizziness
Lung and upper airways
  • Difficulty breathing
General
  • Stiff or twitching muscles
  • Painful joints
  • Pain in the chest
  • Fits
  • Loss of consciousness
Tel your doctor or a nurse immediately if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What Ropivacaine ReadyfusOR contains

Active ingredient
(main ingredient)		Ropivacaine hydrochloride
Other ingredients
(inactive ingredients)

Sodium chloride

Hydrochloric acid or sodium hydroxide for pH adjustment

Water for injections

Potential allergensN/A

Do not take this medicine if you are allergic to any of these ingredients.

What Ropivacaine ReadyfusOR looks like

Ropivacaine ReadyfusOR containing 250 mL of the 0.2% ropivacaine hydrochloride solution is presented in the pre-filled dispenser. The ropivacaine hydrochloride solution is clear and colourless. (AUST R 267572).

Who distributes Ropivacaine ReadyfusOR

Sponsor:

BioQ Pharma Pty Ltd
225 George Street
Sydney, NSW 2000
Australia

Distributor:

STADA Pharmaceuticals Australia Pty Ltd
40-42 Scott Street
Dandenong, VIC 3175
Australia

This leaflet was prepared in November 2022.

Published by MIMS February 2023

BRAND INFORMATION

Brand name

Ropivacaine ReadyfusOR

Active ingredient

Ropivacaine hydrochloride

Schedule

S4

 

Notes

Distributed by STADA Pharmaceuticals Australia Pty Ltd

1 Name of Medicine

Ropivacaine hydrochloride.

2 Qualitative and Quantitative Composition

Ropivacaine ReadyfusOR 0.2% solution for injection is a sterile, isotonic, isobaric, aqueous solution of ropivacaine HCl.
The pH of the solution is adjusted with sodium hydroxide or hydrochloric acid to remain between 4.0-6.0 during the approved shelf-life and the nominal osmolality of the injection is 288 mOsm/kg.
The solution is preservative free.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

The solution for injection is a clear and colourless liquid, practically free from particles.

4 Clinical Particulars

4.1 Therapeutic Indications

Ropivacaine ReadyfusOR (0.2% ropivacaine solution for injection) is indicated for:
Continuous peripheral nerve block infiltration for postoperative pain management in adults.
Continuous wound infiltration for postoperative pain management in adults.
There are no safety or efficacy data to support the use of Ropivacaine ReadyfusOR for analgesia for longer than 72 hours. (Data for peripheral nerve block administered as a continuous peripheral infusion and for continuous wound infusion support the use for up to 48 hours only).

4.2 Dose and Method of Administration

Ropivacaine should only be used by or under the supervision of clinicians experienced in regional anaesthesia.
The presentation of 0.2% ropivacaine hydrochloride solution for injection in the Ropivacaine ReadyfusOR is for single use in one patient only. Discard any residue. The Ropivacaine ReadyfusOR dispenser should be discarded after single use.
The lowest dosage that results in effective anaesthesia should be used and should be based on the status of the patient and the type of regional anaesthesia intended. In general, surgical anaesthesia requires the use of higher concentrations and doses than those required for analgesia.
Table 1 is a guide to dosage. The clinician's experience and knowledge of the patient's physical status are of importance when deciding the dose.

Adults.

See Table 1.
The appropriate concentration and volume for each procedure should be selected. For further details of procedures please see current standard textbooks.

Note.

Analgesia.

When calculating the dosage for postoperative analgesia, the use of intraoperative local anaesthetic/s should be taken into account. For treatment of postoperative pain, the following technique can be recommended:
When prolonged peripheral nerve blocks are applied, either through continuous infusion or through repeated injections, the risk of reaching a toxic plasma concentration or inducing local neural injury must be considered.
In clinical studies, femoral nerve block was established with 300 mg ropivacaine 0.75% (7.5 mg/mL) and interscalene block with 225 mg ropivacaine 0.75% (7.5 mg/mL), respectively, before surgery. Analgesia was then maintained with 0.2% (2 mg/mL). Infusion rates or intermittent injections of 10-20 mg per hour for 48 hours provided adequate analgesia and were well tolerated.

Use in children.

Ropivacaine ReadyfusOR is not indicated for use in children.

Use in debilitated or elderly patients.

Debilitated or elderly patients, including those with partial or complete heart conduction block, advanced liver disease or severe renal dysfunction should be given reduced dosage commensurate with their physical condition. Clinical studies with this group of patients have not been performed (see Section 4.4 Special Warnings and Precautions for Use).

4.3 Contraindications

1. Allergy or hypersensitivity to amide type local anaesthetics. Detection of suspected hypersensitivity by skin testing is of limited value.
2. Intravenous administration.
3. Local anaesthetics are contraindicated for epidural and spinal anaesthesia in patients with uncorrected hypotension.
4. Local anaesthetic techniques must not be used when there is inflammation and/or sepsis in the region of the proposed injection and/or in the presence of septicaemia.
5. Intravenous regional anaesthesia (Bier's block) as unintentional passage of local anaesthetic into the systemic circulation, despite the use of a tourniquet, may cause systemic toxic reactions.
6. The use of ropivacaine is not recommended for obstetric paracervical block.
7. General contraindications related to epidural anaesthesia, regardless of the local anaesthetic used, should be taken into account.
8. Intravascular use.
9. Intrathecal use.
10. Intracerebral use.
11. Intra-articular use.

4.4 Special Warnings and Precautions for Use

1. When any local anaesthetic agent is used, resuscitative equipment and drugs, including oxygen, should be immediately available in order to manage possible adverse reactions involving the cardiovascular, respiratory or central nervous systems. Because of the possibility of hypotension and bradycardia following major blocks, an IV cannula should be inserted before the local anaesthetic is injected.
2. Injection should always be made slowly with frequent aspirations to avoid inadvertent intravascular injection which can produce toxic effects.
3. Although intra-articular continuous infusions of local anaesthetics following arthroscopic and other surgical procedures is an unapproved use, there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in paediatric and adult patients following intra-articular continuous infusions of local anaesthetics with and without adrenaline for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the second month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement. Therefore, Ropivacaine ReadyfusOR should not be used for postoperative intra-articular continuous infusion.
4. The safety and efficacy of ropivacaine hydrochloride depends on proper dosage, correct technique and adequate precautions. Standard textbooks should be consulted regarding specific techniques and precautions for various regional anaesthetic procedures.
5. Ropivacaine is eliminated primarily by hepatic metabolism and changes in hepatic function may have significant consequences. Ropivacaine has an intermediate to low clearance, which depends on its unbound fraction and intrinsic metabolic clearance. Ropivacaine ReadyfusOR should therefore be used with caution in patients with severe hepatic disease.
6. The lowest dosage that results in efficacious anaesthesia should be used. Elderly, young or debilitated patients, including those with partial or complete heart conduction block, advanced liver disease or severe renal dysfunction, should be given reduced doses commensurate with their age and physical condition.
7. Normally there is no need to modify the dose in patients with impaired renal function when used for single dose or short term treatment. Acidosis and reduced plasma protein concentration, frequently seen in patients with chronic renal dysfunction may increase the risk of systemic toxicity (see Section 4.2 Dose and Method of Administration).
8. Certain local anaesthetic procedures such as injection in the head and neck region, including retrobulbar, dental and stellate ganglion blocks, may be associated with a higher frequency of serious adverse reactions, regardless of the local anaesthetic used. The side effects may be similar to the systemic toxicity seen with unintentional intravascular injections of larger doses.
9. Ropivacaine ReadyfusOR should be used with caution in patients with known drug sensitivities.
10. Careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness should be accomplished after each local anaesthetic injection. It should be kept in mind that at such times restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression or drowsiness may be early warning signs of CNS toxicity.
11. Major peripheral nerve blocks may involve the administration of a large volume of local anaesthetic in highly vascularised areas, often close to large vessels where there is an increased risk of intravascular injection and/or rapid systemic absorption. This can lead to high plasma concentrations.
12. If the Ropivacaine ReadyfusOR is administered simultaneously by two or more different routes, the total dose and hence the risk of systemic toxicity should be considered.
13. Patients treated with class III anti-arrhythmic drugs (e.g. amiodarone) should be under close surveillance. ECG monitoring should also be considered, since cardiac effects may be additive.
14. There have been reports of cardiac arrest during the use of ropivacaine products for epidural anaesthesia or peripheral nerve blockade, especially after unintentional accidental intravascular administration in elderly patients and in patients with concomitant heart disease. In some instances, resuscitation has been difficult. Should cardiac arrest occur, prolonged resuscitative efforts may be required to improve the possibility of a successful outcome.
15. Ropivacaine is possibly porphyrinogenic and should only be prescribed to patients with acute porphyria when no safer alternative is available. Appropriate precautions should be taken in the case of vulnerable patients.

Use in renal impairment.

See Section 4.4 Special Warnings and Precautions for Use, 7 above.

Use in the elderly.

See Section 4.4 Special Warnings and Precautions for Use, 6 above.

Paediatric use.

Ropivacaine ReadyfusOR is not indicated for use in children.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Local anaesthetics and antiarrhythmic drugs.

Ropivacaine ReadyfusOR should be used with caution in patients receiving other local anaesthetics or agents structurally related to amide type local anaesthetics, since the toxic effects are additive. Specific interaction studies with Ropivacaine ReadyfusOR and class III anti-arrhythmic drugs (e.g. amiodarone) have not been performed, but caution is advised (see Section 4.4 Special Warnings and Precautions for Use, 11).

Adrenaline.

The duration and intensity of ropivacaine sensory block is not improved by the addition of adrenaline.

Alkaline solutions.

The solubility of ropivacaine is limited at pH values above 6.0. This must be taken into consideration if adding an alkaline solution since precipitation might occur at higher pH values.

Cytochrome P450 interactions (see Section 5.2 Pharmacokinetic Properties).

Ropivacaine is metabolised by the enzymes CYP1A2 and CYP3A4. Interactions with inducers of these enzymes are not expected to be clinically relevant, however there is a potential for metabolic interaction when ropivacaine is used in combination with a potent enzyme inhibitor.

CYP1A2 inhibitors.

Fluvoxamine.

Oral fluvoxamine treatment caused a 70% decrease in ropivacaine clearance and a 3-fold higher AUC in healthy volunteers. Single administrations of ropivacaine should be used with care in patients who are concomitantly receiving a potent CYP1A2 inhibitor. Repeated administration or long term infusion should be avoided in such patients.
A theoretical possibility of metabolic drug interactions with potent inhibitors of CYP1A2, such as enoxacin, may exist.

CYP3A4 inhibitors.

Ketoconazole.

Co-administration with ketoconazole, a potent inhibitor of CYP3A4, has been shown to cause a marginal (15%) decrease in ropivacaine clearance in healthy volunteers.

Theoretical interactions.

Cimetidine, an inhibitor of CYP2E1, did not inhibit the formation of 3-hydroxyropivacaine but inhibited some formation of minor metabolites in vitro.

Metabolic interactions.

With the low to intermediate hepatic extraction ratio of ropivacaine (mean 0.4), a fall in the liver blood flow is not expected to have a significant influence on ropivacaine clearance.

Clinical relevance of interactions.

In the clinical experience with ropivacaine, patients usually received ropivacaine in combination with several other therapies. The safety evaluation of ropivacaine is therefore based upon its use in combination with various concomitant treatments. The review of safety data in these studies show that ropivacaine has a safety profile comparable to other amide local anaesthetics used for regional anaesthesia.
These data did not indicate any specific drug interactions that would require special study for the use of ropivacaine as a single-dose or for treatment for less than 24 hours. Furthermore, drugs metabolised by CYP1A2, e.g. paracetamol, have also been used in combination with ropivacaine in the clinical program, without clinical evidence of metabolic interactions (see Section 5.2 Pharmacokinetic Properties).

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No adverse effects on fertility and reproductive performance were seen in rats over 2 generations following daily subcutaneous administration of ropivacaine from prior to mating through weaning, with estimated systemic exposure (plasma AUC) twice the clinical exposure following a 200 mg epidural dose. Increased pup loss in the first 3 days post-partum was attributed to reduced maternal care.
(Category B1)
There was no evidence of teratogenicity following daily subcutaneous administration of ropivacaine to rats and rabbits during the period of organogenesis, with estimated systemic exposure (plasma AUC) twice the clinical exposure following a 200 mg epidural dose. In rats treated similarly with ropivacaine daily from late gestation to weaning, there were no treatment-related effects on late foetal development, parturition, lactation, neonatal viability, or offspring growth. In rats treated from late gestation to weaning, maternal toxicity was elicited at a lower dose and lower unbound plasma concentration with bupivacaine than with ropivacaine.
There are no clinical studies in pre-term pregnant women on the effects of ropivacaine on the developing foetus. Ropivacaine should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
The epidural use of ropivacaine in obstetrics is well documented and adverse effects have been reported (see Section 4.8 Adverse Effects (Undesirable Effects), Foetal, neonatal and infant adverse events).
Intrathecal administration has not been documented for caesarean section.
 Subcutaneous administration of ropivacaine to rats from late gestation to weaning, with estimated systemic exposure (plasma AUC) twice the clinical exposure following a 200 mg epidural dose, did not affect late foetal development, parturition, lactation, neonatal viability, or offspring growth. Ropivacaine and/or its metabolites are excreted into milk in rats, but excretion into human milk has not been investigated.

4.7 Effects on Ability to Drive and Use Machines

Depending on the dose, local anaesthetics may have a mild effect on mental function and coordination even in the absence of overt CNS toxicity and may temporarily impair locomotion and alertness. Patients should be warned of this possibility and advised not to drive a motor vehicle or operate machinery if affected.

4.8 Adverse Effects (Undesirable Effects)

Adverse events reported in association with ropivacaine are similar in character to those observed with other local anaesthetics of the amide type.
Adverse reactions may be due to high plasma levels as a result of excessive dosage, rapid absorption, delayed elimination or metabolism, or inadvertent intravascular injection. They should be distinguished from the physiological effects of the nerve block itself e.g. a decrease in blood pressure and bradycardia during epidural and intrathecal anaesthesia and events caused by needle puncture (e.g. spinal haematoma, postdural puncture, headache, meningitis and epidural abscess).
Pronounced acidosis, hyperkalaemia or hypoxia in the patient may increase the risk and severity of toxic reactions.
The effects of systemic overdose and unintentional intravascular injection may involve the central nervous system and/or the cardiovascular system (see Section 4.9 Overdose). Inadvertent subarachnoid injection may lead to CNS depression, respiratory arrest and cardiovascular collapse.

Very common events (> 10%).

Cardiovascular.

Hypotensionc.

Gastrointestinal.

Nausea.

Common events (> 1%).

A large number of adverse events have been reported during clinical development, the majority related to the expected effects of the block and to the clinical situation rather than reactions to the drug. Thus hypotension and nausea have been registered in 39% and 25%, respectively, of the patients treated in clinical studies.
The following adverse events are considered to be of clinical importance regardless of causal relationship.

Cardiovascular.

Bradycardiaa, hypertension and tachycardia.

Nervous system.

Paraesthesia, temperature elevation, rigors (chills), headachea and dizziness.

Gastrointestinal.

Vomitinga,d.

Other.

Urinary retentiona, back pain, insomnia, chest pain, pain and oliguria.

Uncommon events (≤ 1%).

Acute systemic toxicity.

More serious but less common reactions that reflect acute systemic toxicityb, include dysarthria, muscular rigidity, muscle twitching, unconsciousness, convulsions, hypoxia, hypercapnia, apnoea, severe hypotension, bradycardia, arrhythmias and cardiac arrest. Indirect cardiovascular effects (hypotension, bradycardia) may occur after epidural administration, depending on the extent of the concomitant sympathetic block.
Convulsions, grand mal convulsions and seizures have been observed following unintended intravascular injection of ropivacaine.
Due to the low doses used for intrathecal anaesthesia, the potential for systemic toxic reactions is expected to be low.

Psychiatric.

Anxiety.

Nervous system.

Hypoaesthesiaa.

Vascular.

Syncopea.

Respiratory, thoracic and mediastinal.

Dyspnoeaa.

General disorders and administration site conditions.

Hypothermiaa.

Rare (≤ 0.1%).

Cardiac disorders.

Cardiac arrest, cardiac arrhythmias.

General disorders and administration site conditions.

Allergic reactions (anaphylactoid reactions, angioneurotic oedema and urticaria).
a These reactions are more frequent after spinal anaesthesia.
b These symptoms usually occur because of inadvertent intravascular injection, overdose or rapid absorption.
c Hypotension is less frequent in children (> 1%).
d Vomiting is more frequent in children (> 10%).

Class related adverse drug reactions.

This section includes complications related to anaesthetic technique regardless of the local anaesthetic used.

Neurological complications.

Neuropathy and spinal cord dysfunctions (e.g. anterior spinal artery syndrome, arachnoiditis, cauda equina syndrome), have been associated with intrathecal and epidural anaesthesia.

Total spinal block.

Total spinal block may occur if an epidural dose is inadvertently administered intrathecally, or if a too large intrathecal dose is administered.

Foetal, neonatal and infant adverse events.

Clinical trials have been conducted in over 400 pregnant women using ropivacaine. These studies recorded all adverse events experienced by the baby in utero, perior postpartum, regardless of causality to ropivacaine, other medications or other factors.
Common events (> 1%).

Cardiovascular.

Foetal distress, foetal tachycardia and foetal bradycardia.

Gastrointestinal.

Neonatal vomiting.

Respiratory.

Neonatal respiratory disorders and neonatal tachypnoea.

Other.

Neonatal fever and neonatal jaundice.
Uncommon events (< 1%).

Metabolic.

Foetal acidosis and neonatal hypoglycaemia.

Other.

Hypotonia, neonatal sepsis and low Apgar score.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Acute emergencies associated with the use of local anaesthetics are generally related to high plasma levels or to unintended subarachnoid injection of the local anaesthetic solution (see Section 4.8 Adverse Effects (Undesirable Effects); Section 4.4 Special Warnings and Precautions for Use).
Accidental intravascular injections of local anaesthetics may cause immediate toxic effects. Toxic effects may also arise from exceptionally rapid absorption from highly vascularised areas. In the event of overdose, peak plasma concentrations may not be reached for one to two hours, depending on the site of the injection and signs of toxicity may thus be delayed.
Systemic toxic reactions may involve the central nervous system and the cardiovascular system.
Early signs of local anaesthetic toxicity may be difficult to detect in cases where the block is given during deep sedation or general anaesthesia.
For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

Symptoms.

Central nervous system toxicity is a graded response with symptoms and signs of escalating severity. Initially symptoms such as visual or hearing disturbances, perioral numbness, dizziness, light headedness, tingling and paraesthesia are seen. Dysarthria, muscular rigidity and muscular twitching are more serious and may precede the onset of generalised convulsions.
Unconsciousness and grand mal convulsions may follow, which can last from a few seconds to several minutes. Hypoxia and hypercapnia occur rapidly during convulsions due to the increased muscular activity, together with disruption to respiration and possible loss of functional airways. In severe cases apnoea may occur. Respiratory and metabolic acidosis, hyperkalaemia, hypocalcaemia and hypoxia increase and extend the toxic effects of local anaesthetics.
Recovery follows the redistribution of the local anaesthetic drug from the central nervous system and subsequent metabolism and excretion. Recovery should be rapid unless large amounts of the drug have been injected.
Cardiovascular toxicity indicates a more severe situation. Hypotension, bradycardia, arrhythmia and even cardiac arrest may occur as a result of high systemic concentrations of local anaesthetics. In volunteers the intravenous infusion of ropivacaine resulted in signs of depression of conductivity and contractility.
Cardiovascular toxic effects are generally preceded by signs of toxicity in the central nervous system, unless the patient is receiving a general anaesthetic or is heavily sedated with drugs such as benzodiazepines or barbiturates. However in rare cases, cardiac arrest has occurred without prodromal CNS effects.

Treatment.

If signs of acute systemic toxicity occur, injection of the local anaesthetic should be stopped immediately.
Treatment consists of ensuring adequate ventilation and arresting convulsions. Assisted or controlled ventilation should be maintained with oxygen, if required.
If convulsions occur and do not spontaneously stop within 15-20 seconds, an anticonvulsant should be given intravenously e.g. diazepam 5-10 mg IV or where indicated, sodium thiopentone (5 mg/kg). If convulsions interfere with breathing and/or are not rapidly controlled by specific anticonvulsant medication, suxamethonium (1-2 mg/kg) may be used to paralyse the patient. Artificial ventilation must then be instituted.
If cardiovascular depression is evident (hypotension, bradycardia), appropriate treatment with intravenous fluids, vasopressor and or inotropic agents should be considered.
If ventricular fibrillation, cardiac arrest or circulatory arrest occur, cardiopulmonary resuscitation must be instituted and maintained. Optimal oxygenation and ventilation and circulatory support as well as treatment of acidosis are of vital importance.
Should cardiac arrest occur, prolonged resuscitative efforts may be required to improve the possibility of a successful outcome.

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Ropivacaine has both anaesthetic and analgesic effects. At higher doses it produces surgical anaesthesia with motor block, while at lower doses it produces a sensory block including analgesia with little motor block. The duration and intensity of ropivacaine sensory block is not improved by the addition of adrenaline. Ropivacaine, like other local anaesthetics, causes reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the cell membrane of the nerve fibres. It is the first long acting amide local anaesthetic developed as a pure enantiomer. There is no evidence of in vivo racemisation of ropivacaine.

Clinical trials.

The local anaesthetic effect of ropivacaine and its [R-(+) enantiomer] was evaluated for sciatic block, spinal anaesthesia and infiltration anaesthesia over a wide concentration range (0.25-1.0%) in a number of animal species and a concentration-(dose-) response relationship was ascertained. These studies supported the selection of the enantiomerically pure drug ropivacaine and are consistent with the observations with other local anaesthetics that the [S-(-) form] is less toxic and/or has a longer duration of action than the [R-(+) form].
In vitro testing of ropivacaine conduction anaesthesia indicate that ropivacaine is comparable to, or slightly more potent than, bupivacaine in blocking sensory fibres and is less active in blocking motor fibres.
The anaesthetic effects of ropivacaine were evaluated in peripheral (sciatic nerve and brachial plexus) and central (spinal and epidural) neural blocks, as well as in infiltration and topical anaesthesia in a large number of studies using multiple animal species including mouse, rat, guinea-pig, dog, sheep and Rhesus monkey. The peripheral neural block studies indicate that a concentration of ropivacaine of 0.5-1.0% consistently produces effective sensory and motor block. Neither increasing concentration above 0.75% nor adding adrenaline significantly improved the duration of motor block or anaesthesia with ropivacaine.
For central neural blockade, for all species studied, it appeared that onset times of epidural anaesthesia with ropivacaine and bupivacaine were similar. The concentration required to consistently produce complete motor blockade with epidural anaesthesia appeared to be 0.75%-1.0% for ropivacaine. Duration of sensory block appeared to be comparable for equal concentrations of ropivacaine and bupivacaine.
Tests of infiltration anaesthesia in guinea-pigs showed that ropivacaine was markedly superior to bupivacaine in producing sustained cutaneous anaesthesia at all concentrations. The duration of anaesthesia produced with the least effective ropivacaine concentration (0.25%) far exceeded that produced by the highest bupivacaine concentration (0.75%).
For analgesia, the potency of ropivacaine is similar to that of bupivacaine. For motor block, the potency was found to be around 80% of bupivacaine.
Ropivacaine and bupivacaine are equipotent in producing seizures in rats and dogs. In both pregnant and non-pregnant sheep, ropivacaine was less toxic than bupivacaine.
Comparisons with the short acting local anaesthetic lignocaine shows that the doses needed to produce seizures are 2 (in sheep) to 4 (in rats and dogs) times the dose of ropivacaine. In studies in sheep, ropivacaine appears to have less central nervous system and cardiovascular toxicity than bupivacaine, and pregnancy does not appear to enhance sensitivity in either the central nervous system or in cardiac membranes as has been reported in some studies with bupivacaine.
In vitro heart studies indicate that the effects of ropivacaine on conduction and contractility are less compared to bupivacaine. The risk of ventricular tachycardia is less with ropivacaine than bupivacaine. Atrial and ventricular pacing were more successful during exposure to high concentrations of ropivacaine compared to bupivacaine. The in vitro electrophysiological studies are consistent with the findings in the in vitro heart preparation.
Cardiovascular effects measured in vivo in animal studies showed that ropivacaine is consistently well tolerated and that ropivacaine is less likely than bupivacaine to produce ventricular arrhythmias. Resuscitative measures were highly successful in dogs given large overdoses (9.8 mg/kg given intravenously) of ropivacaine. In most preclinical studies of the cardiovascular effects, comparisons were also made with lignocaine. In general all results were consistent with the observation that a given dose of lignocaine was less toxic than an equivalent dose of ropivacaine or bupivacaine.
In man, ropivacaine is less toxic regarding the CNS and cardiovascular systems than bupivacaine. In two tolerability studies in volunteers given IV infusions, CNS symptoms appeared at higher doses and higher free plasma concentrations of ropivacaine compared to bupivacaine. The ropivacaine dose-response and concentration-response curves for CNS symptoms, e.g. muscular twitching, dysarthria, were consistently shifted to the right compared with those of bupivacaine. A threshold for CNS toxicity was apparent at a free plasma concentration of 0.34 mg/L ropivacaine and 0.13 mg/L bupivacaine. Ropivacaine caused a smaller increase in the QRS width and less pronounced reduction in diastolic and systolic function of the left ventricle as compared to bupivacaine.
2,6-Pipecoloxylidide (PPX) is an active metabolite. The threshold for systemic CNS-toxic unbound plasma concentrations of PPX in rats is about twelve times higher than that of unbound ropivacaine.
Factors which may increase the relative systemic toxicity of local anaesthetics are acidosis and severe hepatic dysfunction.
Ropivacaine, like bupivacaine and other local anaesthetics, produces vasoconstriction at lower concentrations and vasodilation at higher concentrations. These findings appear to be consistent both in vivo and in vitro.

Pharmacodynamic interactions.

In preclinical studies in rats, ropivacaine interacts with agents used in conjunction with regional anaesthesia, such as benzodiazepines, thiopental, enflurane, pancuronium, suxamethonium and fentanyl, in a manner similar to that produced by the commonly used local anaesthetics bupivacaine and lignocaine. In rats, pretreatment with ropivacaine potentiated the sedative effect of morphine compared to placebo.
Pharmacodynamic drug interactions of local anaesthetics probably depend more on the physiological effects of the block, such as hypotension and bradycardia, than on circulating blood levels of the local anaesthetic.

5.2 Pharmacokinetic Properties

The plasma concentration of ropivacaine depends upon the dose, the route of administration and the vascularity of the injection site. Ropivacaine has linear pharmacokinetics and the maximum plasma concentration is proportional to the dose.

Absorption.

Ropivacaine shows complete and biphasic absorption from the epidural space with half-lives of the two phases in the order of 14 minutes and 4 hours. The slow absorption is the rate limiting factor in the elimination of ropivacaine, which explains why the apparent elimination half-life is longer after epidural than after intravenous administration. Ropivacaine shows a biphasic absorption from the caudal epidural space also in children.
The pharmacokinetic profile of ropivacaine in adults following experimental IV administration is summarised in Table 2.

Distribution.

Ropivacaine is mainly bound to α1-acid glycoprotein in plasma with an unbound pharmacologically active fraction of about 6%. An increase in total plasma concentrations during continuous postoperative epidural infusion and interscalene infusion has been observed. This increase is related to a postoperative increase of α1-acid glycoprotein. Variations in unbound concentration of ropivacaine have been much less than in total plasma concentration.

Metabolism.

Ropivacaine is extensively metabolised, predominantly by aromatic hydroxylation. In total, 86% of the dose is excreted in the urine after intravenous administration, of which only about 1% is unchanged drug. Approximately 9% is excreted in faeces.
Both the dealkylation (N-depropylated or PPX) and the hydroxylation pathways in the metabolism of ropivacaine are detoxification reactions. PPX is considered to have approximately one twelfth of the pharmacological activity of ropivacaine. The hydroxylated metabolites of ropivacaine have some local anaesthetic activity (ropivacaine > 3-hydroxyropivacaine >> 4-hydroxyropivacaine). The hydroxylated metabolites are rapidly conjugated in human plasma and are very unlikely to have any pharmacological or toxicological activities.
The major metabolite is 3-hydroxyropivacaine. This metabolite accounts for about 37% of urinary excretion, mainly as a glucuronide conjugate. The only metabolite which reaches detectable concentrations in plasma is 3-hydroxyropivacaine (conjugated and unconjugated). Urinary excretion of 4-hydroxyropivacaine, the N-dealkylated metabolite and the 4-hydroxy-dealkylated metabolite accounts for 1-3% of a given dose.
The NADPH-dependent metabolism of ropivacaine to 3-hydroxyropivacaine is catalysed by CYP1A2. The formation of minor metabolites in vivo is catalysed by CYP3A4. The apparent Km (affinity constant) for 3-hydroxyropivacaine is 16 microM and about 400 microM for the other metabolites. Of the two members in the CYP1A family, CYP1A1 is expressed only after exposure to inducers, while CYP1A2 accounts for about 10% of total P450 in the liver (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions, Metabolic interactions).
A similar pattern of metabolites has been found in children above one year.

Excretion.

Impaired renal function has little or no influence on ropivacaine pharmacokinetics. The renal clearance of PPX is significantly correlated with creatinine clearance. A lack of correlation between total exposure, expressed as AUC, with creatinine clearance indicates that the total clearance of PPX includes a non-renal elimination in addition to renal excretion. Some patients with impaired renal function may show an increased exposure to PPX resulting from a low non renal clearance. The potential for toxicity in these patients is dependent on the total dose, dose route and duration of exposure to ropivacaine.

Paediatrics.

The pharmacokinetics of ropivacaine was characterized in a pooled population PK analysis on data in 192 children between 0 and 12 years from six studies (3 on caudals, 2 on epidural infusions, and 1 on ilioinguinal block). Unbound ropivacaine and PPX clearance and ropivacaine unbound volume of distribution initially depend on both body weight and age up to three years of age, after which they depend largely on body weight. The maturation of unbound ropivacaine clearance and unbound ropivacaine volume of distribution by the age of 2 years. The PPX unbound volume of distribution only depends on body weight.
Unbound ropivacaine clearance increases from 2.4 and 3.6 L/h/kg in the newborn and the 1-month neonate to about 8-16 L/h/kg for ages above 6 months, values within the range of those in adults. Total ropivacaine clearance values per kg body weight increase from about 0.10 and 0.15 L/h/kg in the newborn and the 1-month neonate to about 0.3-0.6 L/h/kg beyond the age of 6 months. Unbound ropivacaine volume of distribution per kg body weight increases from 22 and 26 L/kg in the newborn and the 1-month neonate to 42-66 L/kg above 6 months. Total ropivacaine volume of distribution per kg body weight increases from 0.9 and 1.0 L/kg for the newborn and the 1-month neonate to 1.7-2.6 L/kg beyond the age of 6 months. The terminal half-life of ropivacaine is longer, 6 to 5 h in the newborn and the 1-month neonate compared to about 3 h in older children. The terminal half-life of PPX is also longer, from 43 and 26 h in the newborn and the 1-month old neonate to about 15 h in older children.
At 6 months, the breakpoint for change in the recommended dose rate for continuous epidural infusion, unbound ropivacaine clearance has reached 34% and unbound PPX 71% of its mature value. The systemic exposure is higher in neonates and also somewhat higher in infants between 1 to 6 months compared to older children, which is related to the immaturity of their liver function. However, this is partly compensated for by the recommended 50% lower dose rate for continuous infusion in infants below 6 months.
Simulations on the sum of unbound plasma concentrations of ropivacaine and PPX, based on the PK parameters and their variance in the population analysis, indicate that for a single caudal block the recommended dose must be increased by a factor of 2.7 in the youngest group and a factor of 7.4 in the 1 to 10 year group in order for the upper prediction 90% confidence interval limit to touch the threshold for adult systemic toxicity. Corresponding factors for the continuous epidural infusion are 1.8 and 3.8 respectively.
When comparing descriptive data in a trial of caudal/epidural infusions in 10 full term neonates aged 0-30 days, to that in 18 older patients aged 31-180 days, total and unbound ropivacaine was higher and showed higher inter-individual variability, unbound apparent clearance lower and ropivacaine binding to plasma proteins (AAG) was lower. There was a greater relative excretion of ropivacaine in urine. Plasma concentrations of total and unbound PPX were similar but PPX had a longer half-life. The sum of unbound concentrations of ropivacaine and one twelfth of PPX was higher in neonates 0-7 days. While the highest level reached was 0.24 mg/L, this may have been still rising when observations ceased at 72 h (only 4 observations). The systemic CNS toxicity threshold in adults is 0.34 mg/L in a mature nervous system (see Section 5.1 Pharmacodynamic Properties, Clinical trials). It is not known how immaturity of the CNS affects toxic thresholds.
Foetuses exposed to ropivacaine during labour or Caesarean section can be regarded, after they have been born, as neonates with a peak plasma concentration at the time of delivery. The maximum unbound plasma ropivacaine concentrations in the newborn as reflected in the umbilical vein at delivery, 0.03 to 0.11 mg/L, are in the same range as those seen after single caudal block in neonates and support the documentation of ropivacaine in neonates. See Table 3.

Pharmacokinetics during pregnancy at term.

In pregnancy at term, ropivacaine clearance is somewhat lower and its unbound clearance about half of that seen after epidural administration to non-pregnant patients. Accordingly, total Cmax and unbound Cmax are higher in pregnancy. The unbound plasma concentrations in the umbilical vein at delivery were similar to those in the mother and showed a fairly rapid equilibrium. There was no obvious correlation between neonatal neurologic and adaptive capacity scores and unbound or total plasma concentrations in the newborns.

Pharmacokinetics following ropivacaine administration via the ReadyfusOR.

In a bioavailability study conducted by the sponsor, total ropivacaine in plasma, mean Cmax for the 48-hour infusion was 357 nanogram/mL and occurred at 36 hours (median). Mean Cmax for a comparator bolus injection was significantly higher than for the infusion and occurred much earlier (i.e. median = 0.75 hour). In the ropivacaine 5 mL/hour infusion treatment delivered from the ReadyfusOR, mean total plasma ropivacaine concentration appeared to reach steady state by 24 hours, maintaining a concentration of approximately 280 to 300 nanogram/mL from 24 to 48 hours.

Clinical trials.

Adults.

Two open label, randomized uncontrolled clinical studies were performed to document the efficacy and safety of ropivacaine 2 mg/mL in continuous peripheral nerve block for post-operative management up to 48 hours. In total 163 patients were studied, 136 received femoral block and 27 interscalene block. Continuous peripheral nerve blocks with ropivacaine provided effective post-operative pain relief in both studies. Patient satisfaction was reported to be high.
Four open label, randomized studies were performed to investigate the efficacy and safety of ropivacaine 0.5% (5 mg/mL) and other strengths for intrathecal administration in surgical anaesthesia. A total 224 patients were studied, of which 217 patients were valid for safety and 212 for efficacy. In two studies, patients underwent minor orthopaedic, gynaecological or urological surgery suited for spinal anaesthesia. In the other two studies, patients underwent a unilateral hip replacement ropivacaine 15 to 20 mg administered intrathecally was effective and the anaesthetic quality was rated high by surgeons, anaesthetists and patients. The incidence and severity of adverse events reported were not related to dose.

5.3 Preclinical Safety Data

Genotoxicity.

Ropivacaine hydrochloride was negative in the Ames salmonella/mammalian microsome mutagenicity test, human lymphocyte chromosome aberration test, mouse micronucleus test, E. coli differential DNA repair test, E. coli host-mediated DNA repair test in mice, and the somatic mutation and recombination test in Drosophila melanogaster (fruit fly), and weakly mutagenic in the mouse lymphoma test. The clinical use of ropivacaine is unlikely to pose any risk of genotoxicity.

Carcinogenicity.

Long term animal assays of carcinogenic potential have not been performed.

6 Pharmaceutical Particulars

6.1 List of Excipients

Water for Injections, sodium chloride, pH adjustment with sodium hydroxide or hydrochloric acid.

6.2 Incompatibilities

The presentation of 0.2% ropivacaine hydrochloride solution for injection is in the hermetically sealed and pre-filled Ropivacaine ReadyfusOR dispenser and it cannot be admixed with another medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Do not freeze.
The presentation of the Ropivacaine ReadyfusOR 0.2% solution for injection is intended for single use only. The Dispenser should be discarded after single use.

6.5 Nature and Contents of Container

The solution for injection comes in a 250 mL HDPE drug reservoir compressible bottle in a dispenser with an indicator window in the dispenser to show drug level.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

The chemical name for ropivacaine hydrochloride is (-)-(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride.
Ropivacaine hydrochloride was developed as the pure (S)-(-)-isomer and has an enantiomeric purity of > 99% and is a white crystalline powder with a water solubility of about 50 mg/mL. It has a pKa of 8.1 (at 25°C) and a molecular weight of 310.86. The pH of a saturated solution of ropivacaine hydrochloride is 4.5 and that of a 1% (w/v) aqueous solution is 5.0.

Chemical structure.

The chemical formula of ropivacaine hydrochloride is C17H26N2O.HCl.

CAS number.

98717-15-8.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription only medicine.

Summary Table of Changes